An RNA editing system that activates the Wnt signaling pathway

The Cas13d RNA editing system downregulates the expression of Axin1 and Axin2, stabilizes β-Catenin, activates the Wnt signaling pathway, solving the safety and effectiveness of activates the Wnt signaling pathway in the prior art, and achieving high efficiency in lung cell regeneration and repair sex, especially in lung injury-related diseases.

CN118185931BActive Publication Date: 2024-12-03SHANGHAI TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311692085.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-12-14
Filing Date
2023-12-11
Publication Date
2024-12-03
Estimated Expiration
2043-12-11

AI Technical Summary

Technical Problem

The prior art is difficult to safely and effectively activate the Wnt signaling pathway, especially in adults, where traditional small molecule inhibitors cannot target specific tissues or cells, and their safety and drug effectiveness are difficult to guarantee.

Method used

Using a Cas13d-based RNA editing system, the gRNA sequences targeting Axin1 and Axin2 of β-Catenin degradation complex members were designed to downregulate the mRNA levels of Axin1 and Axin2, and stabilize β-Catenin, thereby activate the Wnt signaling pathway and use AAV vectors to perform the Delivery, select the AAV6 serotype to achieve efficient infection of specific cells.

Benefits of technology

It significantly upregulates the activity of Wnt signaling pathway, improves the efficiency of lung cell regeneration and repair, especially in lung injury-related diseases, promotes the proliferation and differentiation of type II alveolar epithelial cells, and reduces the development of pulmonary fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118185931B_ABST
    Figure CN118185931B_ABST
Patent Text Reader

Abstract

The present application relates to the field of gene editing, and in particular to an RNA editing system for activating the Wnt signaling pathway. The present application provides an RNA editing element, including an RNA fragment targeting Axin1 and an RNA fragment targeting Axin2. The present invention constructs a gRNA that simultaneously targets Axin1 and Axin2, which can significantly upregulate Wnt activity compared to a gRNA that targets Axin1 or Axin2 alone. The present invention screened and obtained an AAV6 vector from three different serotypes of AAV vectors, which has relatively high expression intensity and efficiency, and has high infection efficiency for airway epithelial cells and alveolar epithelial cells, while the infection efficiency for immune cells and endothelial cells is very low. The AAV vector is assembled with the Cre‑LoxP recombinase system to co-infect host cells, which is convenient for detecting the knockdown efficiency of Cas13d by fluorescent labeling.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of gene editing, and in particular to an RNA editing system for activating the Wnt signaling pathway. Background Art

[0002] The CRISPR system is an acquired immune defense mechanism found in bacteria, in which the Cas13 protein specifically targets RNA. In March 2018, Konermann of the Salk Institute and Yan et al. of Arbor Biotechnologies isolated a new Cas13 protein called Cas13d from different bacterial species. Cas13d functions by synergizing with gRNA. gRNA consists of two parts, which can be transcribed into a Spacer sequence (about 30 nt in length) that specifically recognizes the target gene and a DR sequence for binding to the Cas13d protein. When the Spacer sequence recognizes the target RNA by complementary base pairing, the Cas13d protein is recruited to a specific location to exert cutting activity, causing the RNA to be degraded. Because Cas13d is smaller in size, with only about 930 amino acids, it is easier to deliver by viral vectors. In 2020, Zhou Haibo et al. used Cas13d to specifically knock down Ptbp1 gene expression in retinal Muller glial cells, and used AAV vectors to achieve retinal ganglion cell regeneration in adults, confirming that Cas13d has the feasibility of in vivo RNA editing.

[0003] On the other hand, taking lung tissue as an example, alveoli are an important place for gas exchange, but they are easily damaged due to close contact with the external environment. Alveoli have two types of epithelial cells, namely Type I alveolarepithelial cells and Type II alveolar epithelial cells. The former are responsible for gas exchange, while the latter reduce alveolar surface tension by secreting surfactants. Under normal conditions, the lungs are highly quiescent tissues, but studies have shown that there are different epithelial stem / progenitor cells in various regions of the lungs. These cells can respond quickly after lung injury and participate in the repair of tracheal and alveolar damage through proliferation and differentiation. These stem / progenitor cells include type II alveolar epithelial cells located in the alveoli, which have the potential to differentiate into type I alveolar epithelial cells; basal cells located in the trachea, which can differentiate into various types of airway epithelial cells; club cells in the airways, which can differentiate into ciliated cells; Bronchioalveolar Stem Cells (BASCs) at the bronchial alveolar junction, which can differentiate into alveolar and airway epithelial cells; stem / progenitor cells located in the distal airways, known as lineage negative epithelial stem / progenitor cells (LNEPs), which have the potential to differentiate into type II alveolar epithelial cells and basal-like cells; in addition, type II alveolar epithelial cells (AT2s) in the alveoli have the potential to differentiate into type I alveolar epithelial cells (AT1s).

[0004] The differentiation fate of these epithelial stem / progenitor cells is closely related to their microenvironment, among which the Wnt / β-catenin signaling pathway is involved in the proliferation and differentiation of stem / progenitor cells. In the influenza model, activation of the Wnt / β-catenin signaling pathway of LNEPs can promote their differentiation into AT2; in addition, the Wnt / β-catenin signaling pathway maintains the stem cell activity of AT2 and promotes the proliferation of AT2. Studies have developed specific antibodies for Frizzled5 to activate the Wnt / β-catenin activity of AT2 cells, which can be seen in organoid systems and bleomycin-injured mouse models to promote the proliferation of AT2 cells.

[0005] The Wnt signaling pathway is a highly conserved signal transduction pathway in organisms, and plays a role in cell proliferation, differentiation, and migration. Studies have shown that activation of the Wnt signaling pathway plays a role in the regeneration of different tissues, such as promoting liver damage repair and skin epidermal renewal. However, how to safely and effectively activate the Wnt signaling pathway in adults is an unresolved issue. Traditional small molecule inhibitors such as CHIR99021 and LiCl can activate the Wnt signaling pathway by inhibiting the activity of GSK3β, but small molecule inhibitors cannot act on specific tissues or cells, and their safety and drug effectiveness cannot be guaranteed. Summary of the invention

[0006] In view of the shortcomings of the prior art described above, in order to solve the technical problem that the Wnt signaling pathway cannot be safely and effectively activated in the prior art, the purpose of this application is to provide an RNA editing system for activating the Wnt signaling pathway, based on the RNA editing of the Cas13 protein CasRx, compared to DNA editing, only changes the RNA level, does not change the DNA sequence, and since RNA has many copies in the cell and is constantly updated, this is a transient regulation method with better safety. The present application selects Cas13d, and designs gRNA sequences specifically targeting β-Catenin degradation complex members Axin1 and Axin2, by transiently downregulating the expression of Axin1 and Axin2 mRNA levels, stabilizing β-Catenin, and activating the Wnt signaling pathway. On the other hand, the present application also selects AAV vectors to deliver editing elements, and by screening different AAV serotypes, screens out AAV serotypes with optimal infection efficiency for specific cells. The editing elements are packaged into AAV vectors and further delivered to adults, ultimately achieving safe and effective regulation of mRNA levels for specific cells, thereby activating the Wnt signaling pathway.

[0007] To achieve the above-mentioned object and other related objects, the present application provides, in a first aspect, an RNA editing element, comprising an RNA fragment targeting Axin1 and an RNA fragment targeting Axin2.

[0008] The second aspect of the present application provides a biomaterial selected from any of the following:

[0009] 1) The biological material is a polynucleotide encoding the aforementioned RNA editing element;

[0010] 2) The biological material is a nucleic acid construct, and the nucleic acid construct contains the polynucleotide of 1);

[0011] 3) The biological material is a host cell, which includes the construct of 2) or the polynucleotide of 1) integrated into its genome.

[0012] The third aspect of the present application provides a gene editing system, comprising: the aforementioned RNA editing element or its encoding gene; and a nuclease or its encoding gene, or a complex of the RNA editing element and the nuclease.

[0013] The fourth aspect of the present application provides a pharmaceutical composition, which includes the aforementioned gene editing system and a pharmaceutically acceptable carrier.

[0014] The fifth aspect of the present application provides the use of the aforementioned RNA editing element, the aforementioned biomaterial, the aforementioned gene editing system or the aforementioned pharmaceutical composition in preparing a product having any one or more of the following functions:

[0015] a) Activate the Wnt pathway;

[0016] b) Treating diseases related to lung injury;

[0017] c) Promote lung regeneration;

[0018] d) Promote the proliferation and differentiation of type II alveolar epithelial cells.

[0019] The sixth aspect of the present application provides a gene editing method, which brings the aforementioned gene editing system into contact with the Axin1 and Axin2 genes to achieve editing of the Axin1 and Axin2 genes.

[0020] The seventh aspect of the present application provides a cell obtained by gene editing through the aforementioned gene editing method; preferably, the cell is a mammalian cell; more preferably, the cell is a lung epithelial stem cell.

[0021] Compared with the prior art, the beneficial effects of this application are:

[0022] 1. The present invention constructs a gRNA that simultaneously targets Axin1 and Axin2, which can significantly upregulate Wnt activity compared to a gRNA that targets Axin1 or Axin2 alone.

[0023] 2. The present invention screened out AAV6 vectors from three different serotypes of AAV vectors, which have relatively high expression intensity and infection efficiency, and have high infection efficiency for airway epithelial cells and alveolar epithelial cells, but very low infection efficiency for immune cells and endothelial cells.

[0024] 3. The AAV vector is assembled with the Cre-LoxP recombinase system and co-infects host cells, making it easy to detect the knock-in efficiency of Cas13d by fluorescent labeling. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1This is the working principle of Cas13d and the structure of gRNA (Konermann S et al. Cell, 2018, 173(3): 665-676).

[0026] Figure 2 This is a schematic diagram of screening gRNA sequences targeting Axin1 and Axin2 in Example 3. CasRx and gRNAs targeting Axin1 and Axin2 were overexpressed in mouse cell lines, and the knockdown effects of different gRNAs on Axin1 and Axin2 were detected by qRT-PCR and Western Blot.

[0027] Figure 3 The effect diagram of knocking down Axin1 and Axin2 to activate Wnt pathway activity is shown in Example 3. The effect of knocking down Axin1 and Axin2 on Wnt pathway activity was explored by a luciferase reporter system using a single gRNA or a combination of gRNAs. The results showed that when Axin1 and Axin2 were knocked down at the same time, the activity of the Wnt signaling pathway could be significantly upregulated.

[0028] Figure 4 AAV structure diagram of Example 4.

[0029] Figure 5 This is a graph showing the percentage of cells infected by AAV in each cell population detected by flow cytometry in Example 4. Different types of AAV serotypes expressing GFP were delivered to mouse lung tissue by endotracheal intubation, and the infection intensity of different AAVs and the infection efficiency of different cell types were compared by flow cytometry, and the AAV6 serotype was finally selected.

[0030] Figure 6 This is a schematic diagram of the proportion of AAV co-infection of the same cell detected by flow cytometry in Example 5.

[0031] Figure 7 This is a diagram of Example 6, in which flow cytometry was used to detect the recombination efficiency of the Split-Cre enzyme system in mice.

[0032] Figure 8 This is the AAV vector packaging strategy of Example 6.

[0033] Fig. 9 This is the AAV6-mediated activation of the Wnt signaling pathway in vivo of Example 6.

[0034] Fig.10 It is that the activation of the Wnt signaling pathway in the preventive experimental group of Example 7 inhibits the development of pulmonary fibrosis.

[0035] Fig.11 The activation of the Wnt signaling pathway in the therapeutic experimental group of Example 7 inhibits the development of pulmonary fibrosis. DETAILED DESCRIPTION

[0036] In order to make the invention purpose, technical scheme and beneficial effect of the present application clearer, the present application is further described below in conjunction with the examples. It should be understood that the examples are only used to explain the present application and are not used to limit the scope of the application. The test methods used in the following examples are conventional methods unless otherwise specified, and those familiar with the technology can easily understand other advantages and effects of the present application from the contents disclosed in this description.

[0037] After extensive exploration and research, this application discovered an RNA editing system that activates the Wnt signaling pathway, and completed this application on this basis.

[0038] On the one hand, the present application provides an RNA editing element, including an RNA fragment targeting Axin1 and an RNA fragment targeting Axin2. The RNA editing element is gRNA. Axin1 and Axin2 serve as a β-Catenin degradation complex. Degrading Axin1 and Axin2 can affect the stability of β-Catenin, activate the Wnt signaling pathway, and thus affect the regeneration process of lung cells.

[0039] In the RNA editing elements provided in the present application, Axin1 and Axin2 both include Exon. Exon is a gene sequence that is preserved during the splicing of pre-mRNA and eventually appears in mature mRNA and can be encoded and translated into protein.

[0040] In the RNA editing element provided in the present application, the RNA editing element includes an RNA fragment targeting the Axin1 Exon region and an RNA fragment targeting the Axin2 Exon region. Preferably, the Axin1 Exon region is selected from Exon2, Exon6, Exon9 or Exon10 of Axin1, and the Axin2 Exon region is selected from Exon2, Exon6, Exon10 or Exon11 of Axin2. More preferably, the Axin1 Exon region is selected from Exon9 of Axin1, and the Axin2 Exon region is selected from Exon10 of Axin2.

[0041] In the RNA editing elements provided in the present application, the encoding gene of the spacer of the RNA fragment targeting Axin1 includes SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQID NO: 15 or SEQ ID NO: 16.

[0042] In some embodiments, the spacer sequence encoding gene targeting Exon2 of Axin1 includes SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. Specifically, it is:

[0043] atcagtgaacaatgagcgctgca(g11, SEQ ID NO: 2);

[0044] atcttggtcatccagtaaggaatgcagtga(g1, SEQ ID NO: 3);

[0045] ctcctgcttcaggaaagtcctgaacaggct(g2, SEQ ID NO: 4);

[0046] gtcacagggctcaagcttcctgaagccact(g3, SEQ ID NO: 5);

[0047] gctcttagtggctggcttggtttgtctgga(g4, SEQ ID NO: 6);

[0048] ataaatgtcagacttaagaaaggaagggta(g5, SEQ ID NO: 7);

[0049] cggccatcatcctcatctgcatcttggt(g13, SEQ ID NO: 8);

[0050] gacacaatgccattgctatccag(g12, SEQ ID NO:9).

[0051] In some embodiments, the gene encoding the spacer sequence of Exon6 targeting Axin1 comprises SEQ ID NO: 10 or SEQ ID NO: 11. Specifically, it is:

[0052] gaccctttgcacgtgctcatccaggatgct(g6, SEQ ID NO: 10);

[0053] tagcactgcagtcttagccacatgcccact(g7, SEQ ID NO: 11).

[0054] In some embodiments, the spacer sequence encoding gene of Exon9 targeting Axin1 includes SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14. Specifically, it is:

[0055] cccacagaaatagtaggccacaacaatgct(g8, SEQ ID NO: 12);

[0056] ggttagcagctccttgaactggcccagggt(g9, SEQ ID NO: 13);

[0057] ccacagaaatagtaggccacaac (g14, SEQ ID NO: 14).

[0058] In some embodiments, the gene encoding the spacer sequence of Exon10 targeting Axin1 comprises SEQ ID NO: 15 or SEQ ID NO: 16. Specifically, it is:

[0059] actcactttcttaaagtagtatctgtagct(g10, SEQ ID NO: 15);

[0060] acatgtacaatatatagaggccc (g15, SEQ ID NO: 16).

[0061] The gene encoding the spacer of the RNA fragment targeting Axin2 includes the sequence shown in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.

[0062] In some embodiments, the spacer sequence encoding gene of Exon2 targeting Axin2 includes SEQ ID NO: 17. Specifically, it is:

[0063] acaagcaaaccagaagtccagcg (g21, SEQ ID NO: 17).

[0064] In some embodiments, the gene encoding the spacer sequence of Exon6 targeting Axin2 comprises SEQ ID NO: 18. Specifically, it is:

[0065] caataataatctgttcccccagg (g25, SEQ ID NO: 18).

[0066] In some embodiments, the gene encoding the spacer sequence of Exon10 targeting Axin2 comprises SEQ ID NO: 19. Specifically, it is:

[0067] cagaaaaagtaggtgacaaccag (g22, SEQ ID NO: 19).

[0068] In some embodiments, the gene encoding the spacer sequence of Exon11 targeting Axin2 comprises SEQ ID NO: 20 or SEQ ID NO: 21. Specifically, it is:

[0069] ttagtctatgaatttcagaaccc(g24, SEQ ID NO: 20);

[0070] attaacttaacacaaacccgagc (g23, SEQ ID NO: 21).

[0071] Preferably, the gene encoding the spacer of the RNA fragment targeting Axin1 includes the sequence shown in SEQ ID NO: 14 (g14), and the gene encoding the spacer of the RNA fragment targeting Axin2 includes the sequence shown in SEQ ID NO: 19 (g22).

[0072] In the RNA editing element provided in the present application, the RNA fragment targeting Axin1 and the RNA fragment targeting Axin2 further include a DR sequence. Preferably, the coding gene of the DR sequence includes the sequence shown in SEQ ID NO: 1. Specifically, it is:

[0073] caagtaaacccctaccaactggtcggggtttgaaac (SEQ ID NO: 1).

[0074] The 5' and 3' ends of the gRNA targeting Axin1 and the gRNA targeting Axin2 both contain DR sequences, and one or more spacer sequences are connected between the two DR sequences; multiple spacer sequences are connected through the DR sequences.

[0075] The CRISPR sequence is composed of a differential sequence (called a spacer sequence) integrated into the phage gene fragment and a direct repeat scaffold sequence (called a Scaffold or DR, Direct Repeat) used to bind to the Cas protein. The CRISPR sequence will be transcribed into a guide RNA (gRNA) precursor sequence (pre-gRNA). After being processed into a mature gRNA, the gRNA specifically recognizes the exogenous sequence that can be paired with it through complementary base pairing and mediates the Cas protein to cut it, thereby resisting the re-infection of the same phage.

[0076] The working principle of Cas13d is as follows Figure 1 As shown in A. In this application, the gRNA is constructed into a plasmid vector that can be expressed in mammalian cells. The specific structure is to insert a 23nt spacer sequence that can specifically target Axin between two DR sequences. The two DR sequences are mainly used to simulate the immature gRNA precursor sequence, such as Figure 1 As shown in B.

[0077] In the RNA editing elements provided in the present application, the genes encoding the RNA fragments targeting Axin1 include sequences shown in SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 or SEQ ID NO: 35.

[0078] In some embodiments, the gene encoding the gRNA targeting Exon2 of Axin1 includes SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 or SEQ ID NO: 28. Specifically, it is:

[0079] caagtaaacccctaccaactggtcggggtttgaaacatcagtgaacaatgagcgctgcacaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g11, SEQ ID NO: 22);

[0080] caagtaaacccctaccaactggtcggggtttgaaacatcttggtcatccagtaaggaatgcagtgacaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g1, SEQ ID NO: 23);

[0081] caagtaaacccctaccaactggtcggggtttgaaacctcctgcttcaggaaagtcctgaacaggctcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g2, SEQ ID NO: 24);

[0082] caagtaaacccctaccaactggtcggggtttgaaacgtcacagggctcaagcttcctgaagccactcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g3, SEQ ID NO: 25);

[0083] caagtaaacccctaccaactggtcggggtttgaaacgctcttagtggctggcttggtttgtctggacaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g4, SEQ ID NO: 26);

[0084] caagtaaacccctaccaactggtcggggtttgaaacataaatgtcagacttaagaaaggaagggtacaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g5, SEQ ID NO: 27);

[0085] caagtaaacccctaccaactggtcggggtttgaaaccggccatcatcctcatctgcatcttggtcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g13, SEQ ID NO: 28);

[0086] caagtaaacccctaccaactggtcggggtttgaaacgacacaatgccattgctatccagcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g12, SEQ ID NO: 29).

[0087] In some embodiments, the gene encoding the gRNA targeting Exon6 of Axin1 includes SEQ ID NO: 30 or SEQ ID NO: 31. Specifically, it is:

[0088] caagtaaacccctaccaactggtcggggtttgaaacgaccctttgcacgtgctcatccaggatgctcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g6, SEQ ID NO: 30);

[0089] caagtaaacccctaccaactggtcggggtttgaaactagcactgcagtcttagccacatgcccactcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g7, SEQ ID NO: 31).

[0090] In some embodiments, the gene encoding the gRNA targeting Exon9 of Axin1 includes SEQ ID NO: 32, SEQ ID NO: 33 or SEQ ID NO: 34. Specifically, it is:

[0091] caagtaaacccctaccaactggtcggggtttgaaaccccacagaaatagtaggccacaacaatgctcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g8, SEQ ID NO: 32);

[0092] caagtaaacccctaccaactggtcggggtttgaaacggttagcagctccttgaactggcccagggtcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g9, SEQ ID NO: 33);

[0093] caagtaaacccctaccaactggtcggggtttgaaacccacagaaatagtaggccacaaccaagtaaacccctaccaactggtcggggtttgaaacttttt (gRNA encoding gene for g14, SEQ ID NO: 34).

[0094] In some embodiments, the gene encoding the gRNA targeting Exon10 of Axin1 includes SEQ ID NO: 35 or SEQ ID NO: 36. Specifically, it is:

[0095] caagtaaacccctaccaactggtcggggtttgaaacactcactttcttaaagtagtatctgtagctcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g10, SEQ ID NO: 35);

[0096] caagtaaacccctaccaactggtcggggtttgaaacacatgtacaatatatagaggccccaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g15, SEQ ID NO: 36).

[0097] In the RNA editing element provided in the present application, the gene encoding the RNA fragment targeting Axin2 includes a sequence as shown in SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40 or SEQ ID NO: 41.

[0098] In some embodiments, the gene encoding the gRNA targeting Exon2 of Axin2 includes SEQ ID NO: 37. Specifically, it is:

[0099] caagtaaacccctaccaactggtcggggtttgaaacacaagcaaaccagaagtccagcgcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g21, SEQ ID NO: 37).

[0100] In some embodiments, the gene encoding the gRNA targeting Exon6 of Axin2 includes SEQ ID NO: 38. Specifically, it is:

[0101] caagtaaacccctaccaactggtcggggtttgaaaccaataataatctgttcccccaggcaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g25, SEQ ID NO: 38).

[0102] In some embodiments, the gene encoding the gRNA targeting Exon10 of Axin2 includes SEQ ID NO: 39. Specifically, it is:

[0103] caagtaaacccctaccaactggtcggggtttgaaaccagaaaaagtaggtgacaaccagcaagtaaacccctaccaactggtcggggtttgaaacttttt (gRNA encoding gene for g22, SEQ ID NO: 39).

[0104] In some embodiments, the gene encoding the gRNA targeting Exon11 of Axin2 includes SEQ ID NO: 40 or SEQ ID NO: 41. Specifically, it is:

[0105] caagtaaacccctaccaactggtcggggtttgaaacttagtctatgaatttcagaaccccaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene of g24, SEQ ID NO: 40);

[0106] caagtaaacccctaccaactggtcggggtttgaaacattaacttaacacaaacccgagccaagtaaacccctaccaactggtcggggtttgaaac (gRNA encoding gene for g23, SEQ ID NO: 41).

[0107] Preferably, the gene encoding the RNA fragment targeting Axin1 includes the sequence shown in SEQ ID NO:34, and the gene encoding the RNA fragment targeting Axin2 includes the sequence shown in SEQ ID NO:39.

[0108] In the RNA editing element provided in the present application, the encoding gene includes the sequence shown in SEQ ID NO: 42.

[0109] In a specific embodiment of the present application, the gRNA encoding gene that simultaneously targets Axin1 and Axin2 includes a DR sequence, a g14 sequence, a DR sequence, a g22 sequence, and a DR sequence connected in sequence from the 5' end, and the encoding gene is shown in SEQ ID NO: 42, which is:

[0110] caagtaaacccctaccaactggtcggggtttgaaacccacagaaatagtaggccacaaccaagtaaacccctaccaactggtcggggtttgaaaccagaaaaagtaggtgacaaccagcaagtaaacccctaccaactggtcggggtttgaaacttttt (SEQ ID NO: 42).

[0111] On the other hand, the present application provides a biomaterial selected from any of the following:

[0112] 1) The biological material is a polynucleotide encoding the aforementioned RNA editing element;

[0113] 2) The biological material is a nucleic acid construct, and the nucleic acid construct contains the polynucleotide of 1);

[0114] 3) The biological material is a host cell, which includes the construct of 2) or the polynucleotide of 1) integrated into its genome.

[0115] The construct can usually be obtained by inserting the polynucleotide fragment into a suitable expression vector, and a person skilled in the art can select a suitable expression vector. Expression vectors include, but are not limited to, viral vectors (e.g., viral vectors based on vaccinia virus; poliovirus; adenovirus; adeno-associated virus; SV40; herpes simplex virus; human immunodeficiency virus; retroviral vectors (e.g., murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses, such as Rous sarcoma virus, Harvey sarcoma virus, avian leukemia virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus), etc.

[0116] Any cell suitable for expression by an expression vector can be used as a host cell, which can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Preferably, the host cell is selected from mouse cells and human cells.

[0117] On the other hand, the present application provides a gene editing system, comprising: the aforementioned RNA editing element or its encoding gene; and a nuclease or its encoding gene, or a complex of the aforementioned RNA editing element and the nuclease.

[0118] In the gene editing system provided in the present application, the nuclease is a CRISPR nuclease. Preferably, the nuclease is selected from the Cas9, Cas12, Cas13 protein family or variants thereof. Further preferably, the nuclease is selected from Cas13d.

[0119] In a specific embodiment of the present application, Cas13d, namely CasRx, comes from the intestinal bacterium Ruminococcus flavefaciens XPD3002, and shows stronger specificity and higher knockout efficiency in the RNA cleavage process of mammalian cells in vivo and in vitro. Moreover, CasRx is much smaller than the previously discovered Cas13 protein and is easier to package into AAV vectors for in vivo delivery. Therefore, it has great application prospects in RNA editing.

[0120] In the gene editing system provided in the present application, the gene editing system further comprises a vector, the vector comprising the aforementioned RNA editing element encoding gene and / or a nuclease encoding gene. The vector is an AAV vector.

[0121] like Figure 1 As shown in A, the spacer sequence in the gRNA specifically recognizes the target sequence that can be paired with it through base complementary pairing. The Cas13d protein is recruited to a specific location to exert its cutting activity, causing RNA to be degraded. Since Cas13d is small in size, with only about 930 amino acids, it is easier to deliver by AAV vectors.

[0122] Adeno-Associated Virus (AAV) is a small DNA-containing particle isolated from monkey adenovirus. These particles can only replicate under the condition of co-culture with adenovirus. Its diameter is about 25nm, and it is composed of capsid protein and a single-stranded DNA genome with a length of 4.7kb. It has a good infection effect on skeletal muscle, retina, liver cells, cardiac smooth muscle cells, neuronal cells, pancreatic B cells, joint synovial cells, etc.

[0123] The wild-type AAV genome consists of two open reading frames, encoding Rep and Cap proteins respectively. Rep protein is related to viral replication and is divided into Rep78, Rep68, Rep52 and Rep40, while Cap protein is involved in the assembly of capsid protein. The genome open reading frame is flanked by 145bp inverted terminal repeat sequences (ITRs), which are the only cis-acting elements required for viral genome replication and packaging.

[0124] like Figure 3 As shown, the AAV vector used in this application is obtained by modifying the wild-type AAV vector, and the genome of the AAV itself between the IRT sequences at both ends (i.e., the part encoding the Rep and Cap proteins) is replaced with a promoter and a delivery gene. The promoter includes one or more of CMV, PGK, CAG, EF1α, AFP, and U6. Preferably, the promoter for regulating the expression of nucleases is CMV, and the promoter for regulating RNA editing elements is U6. The AAV vector also includes a WPRE element, which can enhance the stability of the mRNA after transcription of the vector and improve the efficiency of mRNA splicing.

[0125] In a specific embodiment of the present application, the delivery gene in the AAV vector can be GFP or RFP.

[0126] In a specific embodiment of the present application, the delivery gene in the AAV vector can also be a combination of one or more of Cas13d, Ncre, CCre, gRNA, and Cre.

[0127] The AAV vector of the present application is selected from AAV5, AAV6 or AAV9 serotype vectors. Different serotypes have different infection efficiencies and diffusion capabilities in different parts of the body. The appropriate serotype is related to whether the gene can be expressed efficiently and stably, and even to the final research results. Therefore, it is very important to select the appropriate AAV serotype based on the characteristics of cells and each AAV serotype.

[0128] The injection method of AAV vector greatly affects its infection efficiency in animals. Common injection methods include: endotracheal intubation, tail vein injection, intraperitoneal injection, enema, brain stereotaxic injection, in situ injection, etc. Tissue-specific gene regulation can be achieved by selecting a suitable injection method. For specific parts, local in situ injection is usually used, such as brain stereotaxic injection, muscle fixed-point injection, liver parenchyma injection, myocardial in situ injection, eye original injection, intra-articular injection, etc. In a specific embodiment of the present application, the AAV vector is injected into the animal lung tissue through endotracheal intubation.

[0129] In the gene editing system provided in the present application, the gene editing system also includes a Cre enzyme or its encoding gene for tracing. In a specific embodiment of the present application, the Cre enzyme is assembled with a fluorescent gene such as RFP. When the gene editing system successfully infects cells with loxp, the Cre enzyme recognizes the loxp site and RFP can be expressed normally.

[0130] In some embodiments, the AAV vector is generally used together with the Cre-LoxP recombinase system. The AAV vector is assembled with the Cre-LoxP recombinase system and co-infects the host cell, which facilitates the detection of the knockdown efficiency of Cas13d by fluorescent labeling.

[0131] In the gene editing system provided in the present application, the RNA editing element encoding gene and the nuclease encoding gene are located in the same vector. The Cre enzyme encoding gene is not located in the same vector as the RNA editing element encoding gene and the nuclease encoding gene.

[0132] In a specific embodiment of the present application, Figure 8 As shown, when the reporter gene is RFP, the length of the AAV genome itself is limited to no more than 4.7kb. If all the elements to be packaged are packaged into one AAV vector, it will exceed its own length limit. Therefore, the elements are split into two AAV vectors for separate packaging. One AAV vector is equipped with a CMV promoter and its activated Cas13d, a U6 promoter and its activated gRNA, and the other AAV vector is equipped with a CMV promoter and its activated Cre, which is used to recognize loxp sites and express RFP. When both vectors are injected into the host, the infection status of the other vector can be judged by the expression of RFP in one vector.

[0133] On the other hand, the present application provides a pharmaceutical composition, comprising the aforementioned gene editing system and a pharmaceutically acceptable carrier.

[0134] Pharmaceutically acceptable carriers should be compatible with the gene editing system, that is, they can be blended with it without significantly reducing the effect of the pharmaceutical composition. Substances that can be used as carriers include sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethyl cellulose and methyl cellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; colorants; flavorings; tablets, stabilizers, antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffers, etc. These substances can be used to help the stability of the formulation, improve activity or produce an acceptable taste and smell in the case of oral administration as needed.

[0135] On the other hand, the present application provides the use of the aforementioned RNA editing element, the aforementioned biomaterial, the aforementioned gene editing system or the aforementioned pharmaceutical composition in preparing a product having any one or more of the following functions:

[0136] a) Activate the Wnt pathway;

[0137] b) Treating diseases related to lung injury;

[0138] c) Promote lung regeneration;

[0139] d) Promote the proliferation and differentiation of type II alveolar epithelial cells.

[0140] In the application of the present invention, lung injury includes pulmonary fibrosis. The present invention can downregulate pulmonary fibrosis genes, such as Fn1, Col1a1, Col1a2 and Col3a1; and can also downregulate the level of pulmonary fibrosis proteins, such as Fibronectin. In some embodiments, the present invention can reduce the area of ​​fibrosis in immunofluorescence staining, such as myofibroblast ACTA2. + and fibroblast PDGFRb + The area of ​​type II alveolar epithelial cells (SPC) decreased + and type I alveolar epithelial cell RAGE + The area has increased ( Fig.10 HM, Fig.11 HM), which suggests that the activation of the Wnt signaling pathway in epithelial cells promotes the regeneration and repair of alveoli to a certain extent and inhibits the development of pulmonary fibrosis.

[0141] On the other hand, the present application provides a gene editing method, which contacts the aforementioned gene editing system with the Axin1 and Axin2 genes to achieve editing of the Axin1 and Axin2 genes.

[0142] On the other hand, the present application provides a cell obtained by gene editing by the aforementioned gene editing method. Preferably, the cell is a mammalian cell; more preferably, the cell is a lung epithelial stem cell. Specifically, by degrading Axin1 and Axin2, β-catenin can be stabilized, thereby activating the Wnt signaling pathway. Wnt signals affect a variety of physiological and biochemical functions of cells, including lung regeneration function in lung injury diseases. Lung regeneration function includes promoting the proliferation and differentiation of type II alveolar epithelial cells.

[0143] The present application is further described below by way of examples, but the scope of the present application is not limited thereby.

[0144] Unless otherwise indicated, the conventional techniques of molecular biology, microbiology, cell biology, biochemistry, immunology and the like employed in the practice of the present invention are within the understanding and knowledge of the skilled person. These techniques are widely used and can be found in the following literature, such as: "Molecular cloning: A Laboratory Manual, Fourth edition" (MR Green, et al. 2014); "Oligonucleotide Synthesis" (MJ Gait, et al. 1984); "Polymerase Chain Reaction: Principles, Applications and Troubleshooting" (ME Babar, et al. 2011); "Short Protocols in Molecular Biology, Fifth edition" (FM Ausubel, et al. 2002); "Methods in Molecular Biology" (Humana Press); "Gene Transfer Vectors for Mammalian Cells" (JH Miller and M.P. Calos. 1987); "Culture of Animal Cell" (RI Freshney, et al. 2010); "Methods in Enzymology" (Academic Press, Inc); "Using Antibodies: A Laboratory Manual" (E. Harlow and D. Lane. 1999); "Handbook of Experimental Immunology" (LA Herzenberg, et al. 1997); "Current Protocols in Immunology" (JEColigan, et al. 2002).

[0145] Example 1

[0146] In this example, different spacer sequences were designed for different exon positions of Axin1 and Axin2, and the lengths of all of them were 23 nt. The obtained spacer sequences were as follows:

[0147] The encoding gene of the spacer of the RNA fragment targeting Axin1 includes the sequence shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 or SEQ ID NO: 16.

[0148] The gene encoding the spacer of the RNA fragment targeting Axin2 includes the sequence shown in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 21.

[0149] Example 2

[0150] This embodiment constructs a vector containing gRNA and a vector containing Cas13d.

[0151] The 5' and 3' ends of the gRNA targeting Axin1 or Axin2 both contain DR sequences, and one or more spacer sequences are connected between the two DR sequences; multiple spacer sequences are connected through the DR sequences.

[0152] The coding genes of the obtained gRNA are as follows:

[0153] The encoding gene of the gRNA targeting Axin1 includes the sequence shown as SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35 or SEQ ID NO: 36.

[0154] The gene encoding the gRNA targeting Axin2 includes a sequence as shown in SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40 or SEQ ID NO: 41.

[0155] The coding gene for Exon9 of Axin1 and Exon10 of Axin2 simultaneously targets the sequence shown in SEQ ID NO:42.

[0156] The gRNA and Cas13d were respectively constructed into two vectors that can be expressed by mammalian cells, wherein the gRNA-containing vector includes a U6 promoter, a gRNA sequence, an EF1a promoter, and mCherry expressed by the EF1a promoter connected in sequence.

[0157] Among them, the U6 promoter sequence is:

[0158] gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaa gtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggac(SEQ ID NO: 43).

[0159] The EF1a promoter sequence is:

[0160] aaggatctgcgatcgctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgaacgggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacacagctgaagcttcgaggggctcgcatctctccttcacgcgcccgccgccctacctgaggccgccatccacgccggttgagtcgcgttctgccgcctcccgcctgtggtgcctcctgaactgcgtccgccgtctaggtaagtttaaagctcaggtcgagaccgggcctttgtccggcgctcccttggagcctacctagactcagccggctctccacgctttgcctgaccctgcttgctcaactctacgtctttgtttcgttttctgttctgcgccgttacagatccaagctgtgaccggcgcctac(SEQ ID NO:44).

[0161] The sequence of mCherry is:

[0162] atggtgagcaagggcgaggaggataacatggccatcatcaaggagttcatgcgcttcaaggtgcacatggagggctccgtgaacggccacgagttcgagatcgagggcgagggcgagggccgcccctacgagggcacccagaccgccaagctgaaggtgaccaagggtggccccctgcccttcgcctgggacatcctgtcccctcagttcatgtacggctccaaggcctacgtgaagcaccccgccgacatccccgactacttgaagctgtccttccccgagggcttcaagtgggagcgcgtgatgaacttcgaggacggcggcgtggtgaccgtgacccaggactcctccctgcaggacggcgagttcatctacaaggtgaagctgcgcggcaccaacttcccctccgacggccccgtaatgcagaagaagaccatgggctgggaggcctcctccgagcggatgtaccccgaggacggcgccctgaagggcgagatcaagcagaggctgaagctgaaggacggcggccactacgacgctgaggtcaagaccacctacaaggccaagaagcccgtgcagctgcccggcgcctacaacgtcaacatcaagttggacatcacctcccacaacgaggactacaccatcgtggaacagtacgaacgcgccgagggccgccactccaccggcggcatggacgagct(SEQ ID NO:45).

[0163] The vector containing Cas13d comprises a CAG promoter, SV40 NLS-1, Cas13d, SV40 NLS-2, P2A, and EGFP connected in sequence.

[0164] Among them, the sequence of the CAG promoter is:

[0165]

[0166] The sequence of SV40 NLS-1 is:

[0167] ttaattaagcacgcgtgcgggatccgctcaattcgccgccaccatgcctaaaaagaaaagaaaggtgggttctggt (SEQ ID NO: 47).

[0168] The sequence of Cas13d is:

[0169]

[0170] The sequence of SV40 NLS-2 is:

[0171] ggttctggtctcgagcccaagaagaagaggaaagtcctcgag (SEQ ID NO: 49).

[0172] The sequence of P2A is:

[0173] gctactaacttcagcctgctgaagcaggctggagacgtggaggagaaccctggacct (SEQ ID NO: 50).

[0174] The sequence of EGFP is:

[0175] atggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaa(SEQ ID NO:51).

[0176] Example 3

[0177] In this example, the spacer sequence with the optimal knockdown efficiency was screened.

[0178] First, the knockdown efficiencies of gRNAs targeting Axin1 or Axin2 alone were screened, and the results are shown in Figure 2 C and Figure 2D. The vector containing gRNA and the vector containing Cas13d were transfected into the mouse cell line (Neuro-2a, N2a) by liposome transfection (Lipofectamine 2000, Invitrogen, 11668019). The specific experimental steps were as follows: the N2a cells in a 10 cm culture dish were digested and counted the day before transfection and then plated in a 24-well plate with a cell density of about 70%. Cell transfection was performed when the cell density reached 80% after culturing overnight. Taking a single 24-well transfection step as an example, 50ul Opti-MEM I (Invitrogen, 31985062) was taken, 650ng of the vector expressing Cas13d and 350ng of the vector expressing gRNA in Example 2 were added; another 50ul Opti-MEM I was taken, 1.5ul Lipofectamine 2000 was added, and 50ul Opti-MEM I with transfection reagent was mixed into Opti-MEM I with the vector added, and a total of 100ul was evenly added to the cell wells in the form of hanging drops after incubation at room temperature for 15min. After culturing for 72h, the cells were obtained, and the knockdown effects of different gRNAs on Axin1 and Axin2 were detected by qRT-PCR.

[0179] The qRT-PCR screening steps are as follows: RNA is extracted from cells cultured for 72 hours using an RNA extraction kit (Zymo Research, R2062), the RNA is reverse transcribed into cDNA using a reverse transcription reagent (Vazyme, R222-01), and the qRT-PCR system is prepared by adding qRT-PCR reaction enzyme (Vazyme, Q711-03), primers (Axin1, Axin2 and internal reference gene HPRT) and cDNA.

[0180] The upstream primer of Axin1 is: tgtccagtgatgctgacacg (SEQ ID NO: 52), and the downstream primer is: aagtgcgaggaatgtgaggta (SEQ ID NO: 53).

[0181] The upstream primer of Axin2 is: aacctatgcccgtttcctcta (SEQ ID NO: 54), and the downstream primer is: gagtgtaaagacttggtccacc (SEQ ID NO: 55).

[0182] The upstream primer of HPRT is: ctggtgaaaaggacctctcg (SEQ ID NO: 56), and the downstream primer is: tgaagtactcattatagtcaagggca (SEQ ID NO: 57).

[0183] After the qRT-PCR reaction is completed, the threshold cycle number (Cycle threshold, Ct value) of each reaction can be obtained. The Ct value of the target gene is standardized with the Ct value of the internal reference gene, and then the expression level of the same target gene between different samples is compared. The specific calculation process is that the Ct value of the target gene is subtracted from the Ct value of the internal reference gene and recorded as ΔCt, the average value of the ΔCt of the control group is taken, and the average value of the ΔCt of the experimental group minus the ΔCt of the control group is recorded as ΔΔCt. The expression of the target gene in the experimental group compared with the control group is 2^-ΔΔCt. That is, the expression of the target gene in the control group is 1, and the expression of the target gene in the experimental group is compared with that in the control group.

[0184] Figure 2 C and Figure 2 D shows that the knockdown efficiency of Axin1 is 70%-80%, and the knockdown efficiency of Axin2 is 60%-70%. The protein levels of Axin1 and Axin2 can also be seen to decrease significantly ( Figure 2 EF). The spacer sequences with the best knockdown efficiency of gRNA targeting Axin1 or Axin2 were screened, which were g14 targeting Axin1 and g22 targeting Axin2.

[0185] Then, a single gRNA or a combination of gRNAs was used to explore the effect of knocking down Axin1 and Axin2 on the activity of the Wnt pathway through a dual luciferase reporter system (Promega, E1910). When the Wnt signal is activated, the Wnt ligand binds to the seven-transmembrane protein Frizzled (Fz) and low-density lipoprotein receptor-related protein (LRP), activating the downstream cell signal transduction factor Dishevelled (Dvl), further phosphorylating GSK3β, inhibiting the phosphorylation of β-catenin by the degradation complex formed by CK1, GSK3β, Axin and APC, causing β-catenin in the cytoplasm to accumulate and transport to the nucleus, binding to TCF / LEF transcription factors, and activating the expression of downstream target genes.

[0186] The dual luciferases are Renilla luciferase expressed in Renilla plasmid vector and firefly luciferase that can be expressed in 8XTOP plasmid vector. The Renilla luciferase expressed in Renilla plasmid vector is used as the experimental internal reference. In the 8XTOP plasmid vector, the firefly luciferase element is preceded by 8 repeated TCF / LEF fragments, that is, when the Wnt signal is activated, β-catenin accumulates and transports to the nucleus and binds to the TCF / LEF transcription factor to activate the expression of firefly luciferase. CasRx and pre-gRNA were overexpressed in N2a cells, and 8XTOP and Renilla plasmids were transfected 24 hours after transfection. The transfection steps are as described above. After another 48 hours, the cells were obtained, lysed with the lysis buffer in the kit, and the firefly luciferin substrate was added. The chemiluminescence value was read by a microplate reader and recorded as Luciferase. Then Stop&Glo Reagent (Promega, E1910) was added to terminate the firefly luciferase reaction and start the sea renilla luciferase reaction. The chemiluminescence value was read by a microplate reader and recorded as Renilla. The Luciferase / Renilla ratio was the intensity of the Wnt signal activity in each sample. The average value of the Luciferase / Renilla ratio of the control group was taken. The average value of the Luciferase / Renilla ratio of the experimental group divided by the Luciferase / Renilla ratio of the control group was the intensity of the Wnt signal activity of the experimental group compared with the control group. The intensity of the Wnt signal activity of the control group was recorded as 1.

[0187] Positive control: The serine at positions 33, 37 and 45 and the threonine at position 41 in β-Catenin were mutated to alanine (SEQ ID NO: 58), so that β-Catenin could not be degraded, which served as the positive control of the experiment.

[0188] The sequence of the mutated β-Catenin is as follows:

[0189]

[0190] The results are as follows Figure 3 As shown in Figure 2, compared with the control, knocking down Axin1 and Axin2 alone can upregulate Wnt activity by about 2-3 times, but knocking down Axin1 and Axin2 simultaneously can significantly upregulate Wnt activity by about 250 times ( Figure 3 A). The positive control significantly upregulated Wnt activity by about 800-fold ( Figure 3 A). The protein level also shows that when Axin1 and Axin2 are knocked down simultaneously, the protein level of β-Catenin is significantly higher than that of knocking down Axin1 or Axin2 alone ( Figure 3 B).

[0191] Example 4

[0192] This example screens AAV serotypes, including AAV5, AAV6, and AAV9.

[0193] like Figure 4 As shown in the figure, the specific AAV structure is to package EGFP initiated by CMV promoter between the ITR sequences at both ends. AAVs of different serotypes are delivered to the lung tissue of mice by endotracheal intubation. The injection dose is 10 11 On the 14th day after infection, the lung tissues of mice were collected and flow cytometry was used to determine the infection intensity of different serotypes of AAV and the infection efficiency of different cell types. Different cell types distinguished by flow cytometry antibodies included CD45 + Immune cells (BD, 564279), CD31 + Endothelial cells (Biolegend, 102449), and CD326 + CD104 in epithelial cells (Biolegend, 118225) + Airway epithelial cells and CD104 - of alveolar epithelial cells (Biolegend, 123610).

[0194] The results are as follows Figure 5 As shown, in mice infected with AAV6, the expression intensity and positive cell ratio of GFP were the highest, and the infection efficiency of airway epithelial cells and alveolar epithelial cells was high, while the infection efficiency of immune cells and endothelial cells was very low ( Figure 5 C). The present invention hopes to activate the Wnt signaling pathway activity of lung epithelial cells through AAV delivery, so AAV6 serotype is selected as the vector for subsequent experiments.

[0195] Example 5

[0196] This example investigates the ratio of two AAV vectors co-infecting the same cell.

[0197] Since the AAV vector packaging size is limited to 4.7 kb, the components to be packaged are considered to be split into two AAV vectors, which can be delivered to the company (PackGene, Paizhen Bio) to use conventional methods to package AAV6-GFP and AAV6-Cre respectively. Both GFP and Cre are expressed by the CMV promoter. After equal amounts are mixed, they are injected into the lung tissue of mice with loxp-Stop-loxp-tdTomato through tracheal intubation. The injection dose is 2×10 11 14 days after infection, the mouse lung tissue was obtained and digested into a single cell suspension using Dispase II (Invitrogen, 17105041), and GFP expression was analyzed by flow cytometry. + Cells and RFP + Co-expression of cells.

[0198] The results are as follows Figure 6 As shown: the vertical axis is GFP and the horizontal axis is RFP. GFP + Cells account for about 13% of living cells (Q1+Q2), RFP + The cells account for about 19% of the living cells (Q2+Q3), among which GFP + All cells were RFP + , while RFP + About 68% (Q2 / (Q2+Q3)) of the cells expressed GFP. GFP and RFP had a high co-expression ratio, indicating that AAV had a high efficiency in co-infecting the same cell.

[0199] Example 6

[0200] This embodiment adopts two different packaging strategies.

[0201] The first packaging strategy: Figure 7 As shown in A, the editing element combined with the Split-Cre enzyme system was delivered to the company (PackGene, Paizhen Bio) and packaged into two AAV vectors by conventional means. After the two AAVs were mixed, they were injected into the lung tissue of mice carrying loxp-stop-loxp-tdTomato through endotracheal intubation at a dose of 2×10 11 vg / mouse. Only when n-Cre and c-Cre are recombined, the Cre enzyme recognizes the loxp site and tdTomato can be expressed normally. 14 days after infection, the mouse lung tissue was obtained and digested into a single cell suspension. PE in epithelial cells was isolated by flow cytometry. + The cells were sorted and the knockdown efficiency was detected by qRT-PCR.

[0202] The streaming results are as follows Figure 7 B shows: PE +The proportion of cells with loxp in the viable cells was only 1.44%, indicating that the efficiency of the Split-Cre enzyme system in assembling a complete Cre enzyme in vivo and undergoing loxp recombination was not high. + The cells were sorted out and the knockdown efficiency was detected by qRT-PCR, which showed that the knockdown efficiency was not high. Therefore, it is considered that the method of combining the editing element with the Split-Cre enzyme system to achieve in vivo tracing and knockdown at the same time is not feasible.

[0203] The second packaging strategy: Figure 8 As shown in the figure, due to the limitation that the genome length of AAV itself does not exceed 4.7kb, two AAV vectors are packaged, one of which (AAV-Cre) is equipped with a CMV promoter and its Cre promoter, which is used to recognize loxp sites. The other AAV vector has the following 4 packaging methods:

[0204] 1. Equipped with CMV promoter and CasRx initiated by it, U6 promoter and non-specific targeting gRNA initiated by it (Non Targeting, NT:

[0205] caagtaaacccctaccaactggtcggggtttgaaacgggtcttcgagaagacctcaagtaaacccctaccaactggtcggggtttgaaacTTTTT, SEQ ID NO: 59);

[0206] 2. Equipped with CMV promoter and its activated CasRx, U6 promoter and its activated gRNA targeting Axin1 and Axin2;

[0207] 3. Equipped with CMV promoter and GFP;

[0208] 4. A CMV promoter and the mutated β-Catenin as described in Example 3 are installed and activated.

[0209] Five types of AAV were packaged separately, and AAV-Cre was mixed with the other four viruses and then injected into mice with the loxp-stop-loxp-tdTomato genotype.

[0210] After packaging, the subsequent steps were the same as the first packaging strategy. PE+ cells in alveolar epithelial cells were sorted out and the activation of Wnt signaling in vivo was verified by qRT-PCR and Western Blot. The results showed that the knockdown efficiency of Axin1 and Axin2 transcription levels mediated by CasRx was about 50% ( Fig. 9A), after knocking down Axin1 and Axin2, the protein level of β-Catenin increased, and the level of phosphorylated β-Catenin decreased ( Fig. 9 B), indicating that the decrease in Axin1 and Axin2 transcription levels can stabilize the level of β-Catenin. Compared with GFP, overexpression of β-Catenin (S>A) can see a 50-fold increase in Ctnnb1 mRNA levels ( Fig. 9 C), and β-Catenin protein levels also increased ( Fig. 9 D).

[0211] As described above, this application uses CasRx to knock down the mRNA levels of Axin1 and Axin2, stabilize β-Catenin, and activate the Wnt signaling pathway. The dual luciferase reporter gene system is used in mouse cell lines to explore the effect of knocking down Axin1 and Axin2 on Wnt activity, proving that the Wnt signaling pathway can be effectively activated when Axin1 and Axin2 are knocked down at the same time. The packaged AAV was injected into mice, proving that knocking down Axin1 and Axin2 can stabilize β-Catenin and activate the Wnt signaling pathway.

[0212] Example 7

[0213] This example uses an animal model.

[0214] Bleomycin was used to induce pulmonary fibrosis in C57BL / 6J mice. 1.6 mg / kg of bleomycin was injected into the mice through endotracheal intubation. In this model, we investigated whether the activation of the Wnt signaling pathway could inhibit the occurrence and development of pulmonary fibrosis and promote the repair of epithelial cell damage.

[0215] The experiment was set up as a preventive experiment and a therapeutic experiment. In the preventive experiment, the AAV of the second packaging method in Example 6 was injected 14 days before bleomycin injury, and the mice were collected on the 14th day ( Fig.10 A), while in the therapeutic experiment, the AAV of the second packaging method in Example 6 was injected on the 6th day after bleomycin injury, and the mice were collected on the 17th day ( Fig.11 A). qRT-PCR, Western Blot and immunofluorescence staining were used to investigate the role of Wnt signaling activation in epithelial cells in the development of fibrosis.

[0216] The results showed that after activation of the Wnt signaling pathway, the expression levels of fibrosis genes Fn1, Col1a1, Col1a2, and Col3a1 were downregulated at the transcriptional level ( Fig.10 DG, Fig.11DG), the protein level of Fibronectin was downregulated, while the expression intensity of SPC was increased ( Fig.10 BC, Fig.11 BC). Immunofluorescence staining showed that the fibrotic area was myofibroblast ACTA2 + and fibroblast PDGFRb + The area of ​​type II alveolar epithelial cells (SPC) decreased + and RAGE in type I alveolar epithelial cells + The area has increased ( Fig.10 HM, Fig.11 HM), which suggests that the activation of the Wnt signaling pathway in epithelial cells promotes the regeneration and repair of alveoli to a certain extent and inhibits the development of pulmonary fibrosis.

[0217] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present application. Anyone familiar with the technology may modify or change the above embodiments without violating the spirit and scope of the present application. Therefore, all equivalent modifications or changes made by a person of ordinary skill in the art without departing from the spirit and technical ideas disclosed by the present invention shall still be covered by the claims of the present application.

Claims

1. An RNA editing element for lung epithelial cells, It is characterized in that The RNA editing element includes an RNA fragment targeting Axin1 and an RNA fragment targeting Axin2; The RNA editing element includes an RNA fragment targeting the Axin1Exon region and an RNA fragment targeting the Axin2Exon region; The coding gene of the spacer of the RNA fragment targeting Axin1 is a sequence shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 or SEQ ID NO: 16; the coding gene of the spacer of the RNA fragment targeting Axin2 is a sequence shown in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO:

21.

2. The RNA editing element according to claim 1, It is characterized in that The coding gene of the spacer of the RNA fragment targeting Axin1 is the sequence shown in SEQ ID NO: 14, and the coding gene of the spacer of the RNA fragment targeting Axin2 is the sequence shown in SEQ ID NO: 19; And / or, the RNA fragment targeting Axin1 and the RNA fragment targeting Axin2 further include a DR sequence.

3. The RNA editing element according to claim 2, It is characterized in that The coding gene of the DR sequence is the sequence shown in SEQ ID NO:

1.

4. The RNA editing element according to claim 1, It is characterized in that The gene encoding the RNA fragment targeting Axin1 is a sequence as shown in SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35 or SEQ ID NO: 36, and the gene encoding the RNA fragment targeting Axin2 is a sequence as shown in SEQ ID NO: 38 or SEQ ID NO:

39.

5. The RNA editing element according to claim 4, It is characterized in that The gene encoding the RNA fragment targeting Axin1 is the sequence shown in SEQ ID NO: 34, and the gene encoding the RNA fragment targeting Axin2 is the sequence shown in SEQ ID NO:

39.

6. The RNA editing element according to claim 1, It is characterized in that The gene encoding the RNA editing element is a sequence shown in SEQ ID NO:

42.

7. A biological material selected from any of the following: 1) The biological material is a polynucleotide, which encodes the RNA editing element according to any one of claims 1 to 6; 2) The biological material is a nucleic acid construct, which contains the polynucleotide described in 1); 3) The biological material is a host cell, which comprises the construct described in 2) or has the polynucleotide described in 1) integrated into its genome.

8. A gene editing system for lung epithelial cells, It is characterized in that The gene editing system comprises: an RNA editing element or a gene encoding the same as claimed in any one of claims 1 to 6; and a nuclease or a gene encoding the same, or a complex of an RNA editing element and a nuclease as claimed in any one of claims 1 to 6.

9. The gene editing system according to claim 8, It is characterized in that The nuclease is a CRISPR nuclease.

10. The gene editing system according to claim 9, It is characterized in that The nuclease is selected from Cas9, Cas12, Cas13 protein family or variants thereof.

11. The gene editing system according to claim 10, It is characterized in that The nuclease is selected from Cas13d.

12. The gene editing system according to claim 8, It is characterized in that The gene editing system further comprises a vector, wherein the vector comprises a gene encoding an RNA editing element according to any one of claims 1 to 6, and / or a gene encoding a nuclease; And / or, the gene editing system also includes a Cre enzyme or a gene encoding it for tracing.

13. The gene editing system according to claim 12, It is characterized in that The vector is an AAV vector.

14. The gene editing system according to claim 13, It is characterized in that The AAV vector is selected from AAV5, AAV6 or AAV9 serotype vectors.

15. The gene editing system according to claim 13, It is characterized in that The AAV vector includes regulatory elements.

16. The gene editing system according to claim 15, It is characterized in that The regulatory elements include cis-acting elements and promoters.

17. The gene editing system according to claim 16, It is characterized in that The cis-acting element includes an inverted terminal repeat sequence; the promoter includes one or more of CMV, PGK, CAG, EF1α, AFP, and U6.

18. The gene editing system according to claim 17, It is characterized in that The promoter regulating the expression of the nuclease is CMV, and the promoter regulating the RNA editing element is U6.

19. The gene editing system according to claim 12, It is characterized in that Also includes: The RNA editing element encoding gene and the nuclease encoding gene are located in the same vector; And / or, the Cre enzyme encoding gene is not located in the same vector as the RNA editing element encoding gene and the nuclease encoding gene.

20. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the gene editing system according to any one of claims 8 to 19, and a pharmaceutically acceptable carrier.

21. Use of the RNA editing element according to any one of claims 1 to 6, the biomaterial according to claim 7, the gene editing system according to any one of claims 8 to 19, or the pharmaceutical composition according to claim 20 in the preparation of a product for treating lung injury-related diseases.